Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
暂无分享,去创建一个
S. Solomon | M. Pfeffer | S. Yusuf | K. Swedberg | C. Granger | J. McMurray | P. Jhund | H. Skali | B. Claggett | D. Castagno | A. Vazir
[1] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[2] Javaid Nauman,et al. Temporal changes in resting heart rate and deaths from ischemic heart disease. , 2011, JAMA.
[3] J. Connell,et al. Resting Heart Rate Pattern During Follow-Up and Mortality in Hypertensive Patients , 2010, Hypertension.
[4] G. Jennings,et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.
[5] Jean-Claude Tardif,et al. Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.
[6] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[7] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[8] P. Poole‐Wilson,et al. Mode of death in heart failure: findings from the ATLAS trial , 2003, Heart.
[9] Michael Böhm,et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.
[10] Salim Yusuf,et al. Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.
[11] X. Jouven,et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. , 2009, The American journal of cardiology.
[12] G. Davey Smith,et al. Secular trends in heart rate in young adults, 1949 to 2004: analyses of cross sectional studies , 2005, Heart.
[13] M. Bernard. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2011 .
[14] K. Swedberg,et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.
[15] P. Poole‐Wilson,et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. , 2005, European heart journal.
[16] P. Armstrong,et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. , 2009, Annals of internal medicine.
[17] S. Solomon,et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. , 2012, Journal of the American College of Cardiology.
[18] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[19] John G F Cleland,et al. Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.
[20] S. Julius,et al. Elevated Heart Rate: A Major Risk Factor for Cardiovascular Disease , 2004, Clinical and experimental hypertension.
[21] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.